Table 1:
BCMA ADCs
| Drug | Trial ID | Patient Population | Regimen | Phase | n | Median Prior Lines (Range) | ORR (%) | ≥VGPR (%) | PFS (months) | AE’s of Interest | Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Belantamab Mafadotin (GSK2857916) | NCT02064387 (DREAMM-1) | RRMM | Monotherapy | 1 | 73 (35 patients in part 2) | NR (67% ≥ 5) | 60a | 51.4a | 12a | Corneal Toxicitya: 63% grade 1 or 2 9% grade 3 | 45 |
| NCT03525678 (DREAMM-2) | 2 | 97 (2.5 mg/kg) | 7 (3–21) | 31 | 19 | 2.9 | Corneal Toxicity: 43% grade 1 or 2 27% grade 3 | 60–61 | |||
| NCT03544281 (DREAMM-6) | 99 (3.4 mg/kg) | 6 (3–21) | 34 | 20 | 4.9 | Corneal Toxicity: 54% grade 1 or 2 20% grade 3 1% grade 4 | |||||
| NCT02064387 (DREAMM-1) | ≥1 prior lines | Combination with Vd or Rd | 1/2 | 18 with BVdb | 3 (1–11) | 78 | 50 | NR | Corneal Toxicity: 44% grade 1 or 2 56% grade 3 | 66 | |
| NCT04484623 (DREAMM-8) | ≥1 prior lines | Combination with Pd or Rd | 1/2 | 60 | 3 (1–5) | 89 | 74 | NR | Corneal Toxicity: 73% grade 3 | 68 | |
| MEDI2228 | NCT03489525 | RRMM | Monotherapy | 1 | 8241 patients treated at MTD (0.14 mg/kg) | NR (2–11) | 66c | 27c | NR | Photophobiac: 41% grade 1 or 2 17% grade 3 or 4 | 48 |
a
At the recommended part 2 dose (3.4 mg/kg)
b
Only the data on the 18 patients treated with BVd (2.5mg/kg belantamab mafadotin) have been presented
c
Represents patients treated at the MTD (0.14mg/kg)
Abbreviations: AE: Adverse event; ORR: Overall response rate; VGPR: Very good partial response; PFS: progression-free survival; RRMM: relapsed refractory multiple myeloma; Vd: bortezomib and dexamethasone; Rd: lenalidomide and dexamethasone; Pd: Pomalidomide dexamethasone;BVd: belantamab mafadotin, bortezomib and dexamethasone; NR: not reported; MTD: maximum tolerated dose